Item 4.01 Changes in Registrant's Certifying Accountant.
(a) Dismissal of Independent Registered Public Accounting Firm
On January 17, 2023, Kho & Patel, Certified Public Accountants, ("Kho"),
resigned as the independent registered public accounting firm of Vitaspring
Biomedical Co. Ltd. (the "Company").
Kho & Patel's report on the financial statements for the fiscal years ended
January 31, 2022 and January 31, 2021, the last reports issued by Kho, contained
no adverse opinion or disclaimer of opinion, and were not qualified or modified
as to uncertainty, audit scope or accounting principle, other than an
explanatory paragraph as to a going concern.
During the fiscal the years ended January 31, 2022 and January 31, 2021, and in
the subsequent interim periods October 31, 2022, July 21, 2022 and April 30,
2022, through January 17, 2023, the date of the resignation of Kho & Patel, (a)
there were no disagreements with Kho & Patel on any matter of accounting
principles or practices, financial statement disclosure or auditing scope or
procedure, which disagreements, if not resolved to the satisfaction of Kho &
Patel, would have caused them to make reference to the subject matter of the
disagreements in its reports on the financial statements for such year and (b)
there were no reportable events as defined in Item 304(a)(1)(v) of Regulation
S-K.
We have provided a copy of the disclosures contained herein to Kho & Patel on
January 27, 2023, and requested Kho & Patel to provide it with a letter
addressed to the U.S. Securities and Exchange Commission stating whether or not
Kho & Patel agrees with the above disclosures. A copy of Kho & Patel's response
letter is attached hereto as Exhibit 16.1.
(b) New Independent Registered Public Accounting Firm
On January 24, 2023, our board of directors approved the engagement of TAAD LLP
("TAAD"), as the Company's new independent registered public accounting firm.
During the Company's most recent fiscal year end and any subsequent interim
period preceding the engagement of TAAD, neither the Company nor anyone acting
on our behalf, has consulted with TAAD regarding either: (i) the application of
accounting principles to a specified transaction, either contemplated or
proposed, (ii) the type of audit opinion that might be rendered on the Company's
financial statements, or (iii) any matter that was either the subject of a
disagreement between the Company and TAAD as described in Item 304(a)(1)(iv) of
Regulation S-K or a reportable event as described in Item 304(a)(1)(v) of
Regulation S-K.
© Edgar Online, source Glimpses